Today: 29 April 2026
Browse Category

NASDAQ:PLRZ 2 December 2025 - 8 December 2025

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. shares surged to $13–15 by early afternoon December 4, more than doubling from the previous close of $7.09, after hitting intraday highs above $18. The rally followed news of a manufacturing milestone for its PL‑14 allergy nasal spray and new preclinical data showing improved mucoadhesion for its naloxone hydrogel. Polyrizon, based in Israel, has no approved products and reported a 2024 net loss of about $1.5 million.
4 December 2025
··
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd shares surged 130% on December 2 after announcing a manufacturing upscaling milestone for its PL‑14 nasal allergy blocker. The stock closed at $7.33, up from $3.16, with trading volume near 150 million shares. The Israeli biotech, which has no approved products or revenue, now trades around $6 pre-market. Polyrizon develops intranasal hydrogel sprays and remains in the pre-commercial stage.
3 December 2025
··
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon Ltd. shares surged 131.96% on December 2, 2025, closing at $7.33 after announcing a key manufacturing milestone for its PL-14 nasal spray. Intraday trading saw prices swing between $5.85 and $8.36 on volume over 148 million shares. The Israeli biotech, still pre-commercial with no approved products or revenue, now holds a market cap near $14–15 million.
2 December 2025
·

Stock Market Today

  • Smart Share Global Withdraws ADS Listing from Nasdaq
    April 29, 2026, 1:50 PM EDT. Smart Share Global Ltd has formally withdrawn its American Depositary Shares (ADS) listing from the Nasdaq Stock Market. The move was confirmed through the filing of Form 25 with the U.S. Securities and Exchange Commission, which notifies the removal of a security from exchange listing and registration. Nasdaq executed the delisting based on regulatory compliance provisions under the Securities Exchange Act of 1934. Smart Share Global, headquartered in Shanghai, China, did not disclose detailed reasons behind the withdrawal. This development marks a significant shift for the Chinese firm's market presence in the United States, raising questions about future listing strategies or market focus.

Latest article

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

Sagtec Global Stock Jumps After Record 2025 Revenue, but Costs Tell a Harder Story

29 April 2026
Sagtec Global reported 2025 audited revenue of $19.1 million, up 49%, driven by strong growth in services. Shares surged 38% to $2.35 in U.S. trading after volatile swings. Operating income dropped 9% to $2.1 million and earnings per share fell to $0.09 from $0.16, reflecting higher costs after the Nasdaq IPO. Net cash from operations rose 187% to $4.1 million.
Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

29 April 2026
The Dow Jones Industrial Average dropped 320 points, or 0.65%, to 48,821.82 Wednesday afternoon, heading for a fifth straight loss as investors awaited the Federal Reserve’s rate decision and major tech earnings. Brent crude surged 7.14% to $119.20 after reports of a possible extended Iran blockade. Boeing and Goldman Sachs weighed on the Dow, while Amazon rose and Microsoft slipped in midday trading.
Go toTop